CA0717341071 - Common Stock
BAUSCH HEALTH COS INC
NYSE:BHC (4/19/2024, 7:04:00 PM)
After market: 8.59 -0.1 (-1.15%)8.69
+0.09 (+1.05%)
Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. The company is headquartered in Laval, Quebec and currently employs 19,900 full-time employees. The firm develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.
BAUSCH HEALTH COS INC
2150 Saint-Elzear Blvd W
Laval QUEBEC H7L 4A8
P: 18003611448
CEO: Joseph C. Papa
Employees: 19900
Website: https://www.bauschhealth.com/
Bausch + Lomb (BLCO) exceeds Q4 2023 expectations and predicts strong financial performance for 2024 with revenue exceeding forecasts. Read more here.
Here you can normally see the latest stock twits on BHC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: